Effects of atypical antipsychotic drugs on body weight and food intake in dopamine D2 receptor knockout mice

Biochemical and Biophysical Research Communications

Volumn 393, Issue 2, 2010, Pages 235-241

  Yoon, Sehyoun ^a   Noh, Jai Sung ^b,c   Choi, Se Young ^d   Baik, Ja Hyun ^a  

^a Korea University   (South Korea)

^b Ajou University School of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

Atypical antipsychotic drugs; Body weight gain; Dopamine D2 receptor; Olanzapine; Risperidone; Schizophrenia; Ziprasidone

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE 2 RECEPTOR; OLANZAPINE; RISPERIDAL QUICKLET; RISPERIDONE; UNCLASSIFIED DRUG; ZIPRASIDONE;

ANIMAL EXPERIMENT; ARTICLE; BODY FAT DISTRIBUTION; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; FOOD INTAKE; LOCOMOTION; MALE; METABOLIC REGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; WEIGHT GAIN; WILD TYPE;

ADIPOSE TISSUE; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY WEIGHT; EATING; MALE; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; PIPERAZINES; RECEPTORS, DOPAMINE D2; RISPERIDONE; THIAZOLES; WEIGHT GAIN;

MUS;

EID: 77649338442     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.01.108     Document Type: Article

References (39)

1. Kapur S., and Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu. Rev. Med. 52 (2001) 503-517
2. Freedman R. Schizophrenia. N. Engl. J. Med. 349 (2003) 1738-1749
3. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., and Weiden P.J. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 156 (1999) 1686-1696
4. Goudie A., Cooper G., and Halford J. Antipsychotic-induced weight gain. Diabetes Obes. Metab. 7 (2005) 478-487
5. Nasrallah H.A. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol. Psychiatry 13 (2008) 27-35
6. Pani L., Pira L., and Marchese G. Antipsychotic efficacy: relationship to optimal D2-receptor occupancy. Eur. Psychiatry 22 (2007) 267-275
7. Roth B.L., Sheffler D.J., and Kroeze W.K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 3 (2004) 353-359
8. Picetti R., Saiardi A., Abdel Samad T., Bozzi Y., and Baik J.H. Borrelli E dopamine D2 receptors in signal transduction and behavior. Crit. Rev. Neurobiol. 11 (1997) 121-142
9. Baik J.H., Picetti R., Saiardi A., Thiriet G., Dierich A., Depaulis A., Lemeur M., and Borrelli E. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature 377 (1995) 424-428
10. Kelly M.A., Rubinstein M., Asa S.L., Zhang G., Saez C., Bunzow J.R., Allen R.G., Hnasko R., BenJonathan N., Grandy D.K., and Low M.J. Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron 19 (1997) 103-113
11. Saiardi A., Bozzi Y., Baik J.H., and Borrelli E. Antiproliferative role of dopamine: loss of D2 receptors causes hormonal dysfunction and pituitary hyperplasia. Neuron 19 (1997) 115-126
12. An J.J., Bae M.H., Cho S.R., Lee S.H., Choi S.H., Lee B.H., Shin H.S., Kim Y.N., Park K.W., Borrelli E., and Baik J.H. Altered GABAergic neurotransmission in mice lacking dopamine D2 receptors. Mol. Cell. Neurosci. 25 (2004) 732-741
13. Kim S.Y., Choi K.C., Chang M.S., Kim M.H., Na Y.S., Lee J.E., Jin B.K., Lee B.H., and Baik J.H. The dopamine D2 receptor regulates the development of dopaminergic neurons via extracellular signal-regulated kinase and Nurr1 activation. J. Neurosci. 26 (2006) 4567-4576
14. Wang G.J., Volkow N.D., Logan J., Pappas N.R., Wong C.T., Zhu W., Netusil N., and Fowler J.S. Brain dopamine and obesity. Lancet 357 (2001) 354-357
15. Comings D.E., Gade R., MacMurray J.P., Muhleman D., and Peters W.R. Genetic variants of the human obesity (OB) gene: association with body mass index in young women, psychiatric symptoms, and interaction with the dopamine D2 receptor (DRD2) gene. Mol. Psychiatry 1 (1996) 325-335
16. Epstein L.H., Temple J.L., Neaderhiser B.J., Salis R.J., Erbe R.W., and Leddy J.J. Food reinforcement, the dopamine D2 receptor genotype, and energy intake in obese and nonobese humans. Behav. Neurosci. 121 (2007) 877-886
17. Stice E., Spoor S., Bohon C., and Small D.M. Relation between obesity and blunted striatal response to food is moderated by TaqIA A1 allele. Science 322 (2008) 449-452
18. K.S. Kim, Y.R. Yoon, H.J. Lee, S. Yoon, S.Y. Kim, S.W. Shin, J.J. An, M. Kim, S.Y. Choi, W. Sun, J.-H. Baik, Enhanced hypothalamic leptin signaling in mice lacking dopamine D2 receptors, J. Biol. Chem., in press. doi:10.1074/jbc.M109.079590.
19. Cope M.B., Nagy T.R., Fernandez J.R., Geary N., Casey D.E., and Allison D.B. Antipsychotic drug-induced weight gain: development of an animal model. Int. J. Obes. 29 (2005) 607-614
20. Allison D.B., and Casey D.E. Antipsychotic-induced weight gain: a review of the literature. J. Clin. Psychiatry 62 (2001) 22-31
21. Graham K.A., Perkins D.O., Edwards L.J., Barrier R.C., Lieberman J.A., and Harp J.B. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am. J. Psychiatry 162 (2005) 118-123
22. Parsons B., Allison D.B., Loebel A., Williams K., Giller E., Romano S., and Siu C. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr. Res. 110 (2009) 103-110
23. Pouzet B., Mow T., Kreilgaard M., and Velschow S. Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharm. Biochem. Behav. 75 (2003) 133-140
24. Baptista T., Araujo de Baptista E., Ying Kin N.M., Beaulieu S., Walker D., Joober R., Lalonde J., and Richard D. Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: bodyweight, food intake, body composition, hormones and glucose tolerance. Brain Res. 957 (2002) 144-151
25. Cooper G.D., Pickavance L.C., Wilding J.P., Harrold J.A., Halford J.C., and Goudie A.J. Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. J. Psychopharm. 21 (2007) 405-413
26. Arjona A.A., Zhang S.X., Adamson B., and Wurtman R.J. An animal model of antipsychotic-induced weight gain. Behav. Brain Res. 152 (2004) 121-127
27. Fell M.J., Marshall K.M., Williams J., and Neill J.C. Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats. J. Psychopharm. 18 (2004) 149-155
28. Fell M.J., Neill J.C., and Marshall K.M. Effects of the classical antipsychotic haloperidol and atypical antipsychotic risperidone on weight gain, the oestrous cycle and uterine weight in female rats. Eur. Neuropsychopharmacol. 14 (2004) 385-392
29. Goudie A.J., Smith J.A., and Halford J.C. Characterization of olanzapine-induced weight gain in rats. J. Psychopharm. 16 (2002) 291-296
30. Baptista T., Mata A., Teneud L., de Quijada M., Han H.W., and Hernandez L. Effects of long-term administration of clozapine on body weight and food intake in rats. Pharm. Biochem. Behav. 45 (1993) 51-54
31. Minet-Ringuet J., Even P.C., Guesdon B., Tome D., and de Beaurepaire R. Effects of chronic neuroleptic treatments on nutrient selection, body weight, and body composition in the male rat under dietary self-selection. Behav. Brain Res. 163 (2005) 204-211
32. Tadori Y., Forbes R.A., McQuade R.D., and Kikuchi T. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur. J. Pharm. 607 (2009) 35-40
33. Masri B., Salahpour A., Didriksen M., Ghisi V., Beaulieu J.M., Gainetdinov R.R., and Caron M.G. Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc. Natl. Acad. Sci. USA 105 (2008) 13656-13661
34. Glatt S.J., Faraone S.V., and Tsuang M.T. Meta-analysis identifies an association between the dopamine D2 receptor gene and schizophrenia. Mol. Psychiatry 8 (2003) 911-915
35. Allen N.C., Bagade S., McQueen M.B., Ioannidis J.P.A., Kavvoura F.K., Khoury M.J., Tanzi R.E., and Bertram L. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat. Genet. 40 (2008) 827-834
36. Silvestri S., Seaman M.V., Negrete J.C., Houle S., Shammi C.M., Remington G.J., Kapur S., Zipursky R.B., Wilson A.A., Christensen B.K., and Seeman P. Increased dopamine D-2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology 152 (2000) 174-180
37. Lavalaye J., Booij J., Linszen D.H., Reneman L., and van Royen E.A. Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia-a [I-123]-IDEX SPECT study. Psychopharmacology 156 (2001) 53-57
38. Terry A.V., Gearhart D.A., Mahadik S.P., Warsi S., and Waller J.L. Chronic treatment with first or second generation antipsychotics in rodents: effects on high affinity nicotinic and muscarinic acetylcholine receptors in the brain. Neuroscience 140 (2006) 1277-1287
39. Kapur S., and Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am. J. Psychiatry 158 (2001) 360-369